SEPTIN9 and colorectal carcinoma: The sensitivity of Epi proColon®, a qRT‐PCR‐based assay to detect methylated SEPT9 in blood approved by both FDA for CRC screening is higher for more advanced colorectal neoplasia, being 11.2%, 35.0%, and 63.0% for AA, Stage I, and Stage II CRCs, respectively.14, 24